Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ATP4A | P20648 | 3/20 | 0.47 |
| ▸ | ATP4B | P51164 | 3/20 | 0.47 |
| ▸ | TDO2 | P48775 | 7/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | PRKACA | P17612 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30179146 | 0.78 | MEN1 (0.57) | MEN1KMT2AATP4AATP4BTDO2 | |
| SCHEMBL29511348 | 0.78 | MEN1 (0.57) | MEN1KMT2AATP4AATP4BTDO2 | |
| SCHEMBL29990729 | 0.78 | MEN1 (0.64) | MEN1KMT2AATP4AATP4BNR4A2 | |
| SCHEMBL20017659 | 0.74 | MEN1 (0.52) | MEN1KMT2AATP4AATP4BTDO2 | |
| SCHEMBL28160319 | 0.71 | PIM1 (0.52) | MEN1KMT2AATP4AATP4BTDO2 | |
| SCHEMBL23175317 | 0.70 | GSK3B (0.71) | MEN1KMT2AGSK3BDYRK1APRKACA | |
| SCHEMBL30554766 | 0.70 | GSK3B (0.56) | MEN1KMT2AATP4AATP4BTDO2 | |
| SCHEMBL29488164 | 0.70 | GSK3B (0.71) | MEN1KMT2AGSK3BDYRK1APRKACA | |
| SCHEMBL21629009 | 0.70 | GSK3B (0.56) | MEN1KMT2AATP4AATP4BTDO2 | |
| SCHEMBL18509943 | 0.70 | MEN1 (0.53) | MEN1KMT2AATP4AATP4BTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | claimed |
| CN-118510517-A | Therapeutically effective combination of FLT3 inhibitor and BCL-2 inhibitor for the treatment of acute myeloid leukemia | 韩美药品有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-112469715-B | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2024-06-11 | — | — | CN | claimed |
| CN-116693506-A | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2023-09-05 | — | — | CN | claimed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | claimed |
| EP-4630122-A1 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | Aptose Biosciences Inc. (CA) | 2025-10-15 | — | — | EP | disclosed |
| US-12433867-B2 | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | HANMI PHARM. CO., LTD. (KR) | 2025-10-07 | — | — | US | disclosed |
| WO-2024124199-A9 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | APTOSE BIOSCIENCES INC. (CA) | 2025-06-12 | — | — | WO | disclosed |
| CN-116693506-B | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2024-11-26 | — | — | CN | disclosed |
| CN-118510517-A | Therapeutically effective combination of FLT3 inhibitor and BCL-2 inhibitor for the treatment of acute myeloid leukemia | 韩美药品有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024124199-A1 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | APTOSE BIOSCIENCES INC. (CA) | 2024-06-13 | — | — | WO | disclosed |
| CN-112469715-B | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-116693506-A | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-116583284-A | Pharmaceutical composition comprising FLT3 inhibitor for the treatment of myelogenous leukemia | 韩美药品株式会社 | 2023-08-11 | — | — | CN | disclosed |
| US-20220110913-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA | HANMI PHARM. CO., LTD (KR) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110913-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA | FLT3, MCL1, HGFAC | MEN1 901/4885KMT2A 11/4885ATP4A 3395/4885 |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | FLT3, MCL1, CSF3R | MEN1 1801/4885KMT2A 791/4885ATP4A 3091/4885 |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | FLT3, MCL1, CSF3R | MEN1 1801/4885KMT2A 791/4885ATP4A 3091/4885 |
| US-12433867-B2 | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | FLT3, MCL1, HGFAC | MEN1 901/4885KMT2A 11/4885ATP4A 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.